The discrete and combined effect of SREBP-2 and SCAP isoforms in the control of plasma lipids among familial hypercholesterolaemia patients - Durst, R.; Jansen, A.; Erez, G.; Bravdo, R.; Butbul, E.; Ben Avi, L.; Shpitzen, S.; Lotan, C.; Leitersdorf, E.; Defesche, J.; Friedlander, Y.; Meiner, V.; et al. (Atherosclerosis, 2006)
Keywords: Atherosclerosis (general aspects, experimental research); Atherosclerosis - blood; Atherosclerosis - etiology; Atherosclerosis - genetics; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Cardiovascular system; Coronary heart disease; DNA - genetics; Familial hypercholesterolaemia; Female; General and cellular metabolism. Vitamins; Genetic polymorphism; Gene–gene interaction; Genotype; Heart; Humans; Hyperlipoproteinemia Type II - blood; Hyperlipoproteinemia Type II - complications; Hyperlipoproteinemia Type II - genetics; Intracellular Signaling Peptides and Proteins - genetics; Israel; Lipids - blood; Male; Medical sciences; Membrane Proteins - genetics; Mutation; Netherlands; Pharmacology. Drug treatments; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; SCAP; Sex Factors; SREBP; Sterol Regulatory Element Binding Protein 2 - genetics; Switzerland; Vasodilator agents. Cerebral vasodilators; Netherlands; Israel; Asia; Europe; Switzerland; Gene–gene interaction; SCAP; SREBP; Familial hypercholesterolaemia; Genetic polymorphism; Variability; Cardiovascular disease; Lipids; Hyperlipoproteinemia; Homozygosity; Vascular disease; Lipoprotein LDL; Binding protein; Atherosclerosis; Cleavage; Gene-gene interaction; Dyslipemia; Human; Linear regression; Metabolic diseases; Cholesterol LDL; Heterozygosity; Genetic disease; Hypercholesterolemia; Risk factor; Mutation; Polymorphism; Sterol